Using ERBB2 as a prognostic indicator for breast and gastric cancers, the most extensively studied cancers, several studies have demonstrated that tumor recurrence, metastasis, and poor overall survival are associated with high serum ERBB2 levels [15,16,37,38,39]. Here, ERBB2 is linked to cancer.